NCT04187898: Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer |
|
|
| Active, not recruiting | 1 | 50 | US | Eflapegrastim, Docetaxel, Taxotere, Cyclophosphamide, Cytoxan | Spectrum Pharmaceuticals, Inc | Neutropenia, Breast Cancer | 07/24 | 07/24 | | |
